# | Title | Journal | Year | Citations |
---|
1 | Interferon pathway in SLE: one key to unlocking the mystery of the disease | Lupus Science and Medicine | 2019 | 194 |
2 | Haematological manifestations of lupus | Lupus Science and Medicine | 2015 | 174 |
3 | A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial | Lupus Science and Medicine | 2015 | 155 |
4 | Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus--the Hopkins Lupus Cohort | Lupus Science and Medicine | 2015 | 140 |
5 | Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results | Lupus Science and Medicine | 2016 | 118 |
6 | Mouse models of lupus: what they tell us and what they don’t | Lupus Science and Medicine | 2018 | 112 |
7 | Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE | Lupus Science and Medicine | 2015 | 103 |
8 | Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA | Lupus Science and Medicine | 2016 | 98 |
9 | 2021 DORIS definition of remission in SLE: final recommendations from an international task force | Lupus Science and Medicine | 2021 | 97 |
10 | Role of early repeated renal biopsies in lupus nephritis | Lupus Science and Medicine | 2014 | 96 |
11 | Type I interferons in host defence and inflammatory diseases | Lupus Science and Medicine | 2019 | 91 |
12 | Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus | Lupus Science and Medicine | 2018 | 87 |
13 | DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus | Lupus Science and Medicine | 2015 | 83 |
14 | Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? | Lupus Science and Medicine | 2017 | 82 |
15 | Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments | Lupus Science and Medicine | 2017 | 82 |
16 | Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies | Lupus Science and Medicine | 2016 | 78 |
17 | Independent association of glucocorticoids with damage accrual in SLE | Lupus Science and Medicine | 2016 | 77 |
18 | TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus | Lupus Science and Medicine | 2018 | 73 |
19 | Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort | Lupus Science and Medicine | 2015 | 70 |
20 | Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements | Lupus Science and Medicine | 2014 | 65 |
21 | Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials | Lupus Science and Medicine | 2014 | 63 |
22 | Lupus community panel proposals for optimising clinical trials: 2018 | Lupus Science and Medicine | 2018 | 62 |
23 | Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort | Lupus Science and Medicine | 2017 | 61 |
24 | Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus | Lupus Science and Medicine | 2016 | 60 |
25 | Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival | Lupus Science and Medicine | 2015 | 59 |
26 | Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort | Lupus Science and Medicine | 2018 | 59 |
27 | Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus | Lupus Science and Medicine | 2016 | 57 |
28 | Which outcome measures in SLE clinical trials best reflect medical judgment? | Lupus Science and Medicine | 2014 | 56 |
29 | 10 most important contemporary challenges in the management of SLE | Lupus Science and Medicine | 2019 | 55 |
30 | Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up | Lupus Science and Medicine | 2014 | 54 |
31 | Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses | Lupus Science and Medicine | 2016 | 54 |
32 | Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lprmice | Lupus Science and Medicine | 2020 | 54 |
33 | Prediction of prognosis and renal outcome in lupus nephritis | Lupus Science and Medicine | 2020 | 53 |
34 | DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity | Lupus Science and Medicine | 2018 | 52 |
35 | Off-label use of rituximab for systemic lupus erythematosus in Europe | Lupus Science and Medicine | 2016 | 51 |
36 | Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus | Lupus Science and Medicine | 2018 | 51 |
37 | Kynurenine pathway is altered in patients with SLE and associated with severe fatigue | Lupus Science and Medicine | 2018 | 51 |
38 | Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE | Lupus Science and Medicine | 2018 | 51 |
39 | Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort | Lupus Science and Medicine | 2016 | 50 |
40 | Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis | Lupus Science and Medicine | 2017 | 49 |
41 | Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss | Lupus Science and Medicine | 2015 | 48 |
42 | Interferon (IFN)-λ is a potential mediator in lupus nephritis | Lupus Science and Medicine | 2016 | 48 |
43 | Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus | Lupus Science and Medicine | 2015 | 47 |
44 | Associates and predictors of pleurisy or pericarditis in SLE | Lupus Science and Medicine | 2017 | 46 |
45 | Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study | Lupus Science and Medicine | 2015 | 45 |
46 | Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials | Lupus Science and Medicine | 2021 | 45 |
47 | Presentation of SLE in UK primary care using the Clinical Practice Research Datalink | Lupus Science and Medicine | 2017 | 42 |
48 | Obstetric antiphospholipid syndrome | Lupus Science and Medicine | 2018 | 42 |
49 | Reduced response to Epstein–Barr virus antigens by T-cells in systemic lupus erythematosus patients | Lupus Science and Medicine | 2014 | 41 |
50 | I too, am America: a review of research on systemic lupus erythematosus in African-Americans | Lupus Science and Medicine | 2016 | 41 |